Free tool
FAERS Monitor: Fexinidazole
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214429 or its brand name (Fexinidazole, Fexinidazole). Reports on generic versions are filed under their own applications.
Reports
13
Serious
13
100% of reports
Hospitalization
5
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure6
- anaemia3
- pyrexia3
- treatment failure3
- asphyxia2
- coma2
- completed suicide2
- headache2
- pneumonia2
- abdominal pain upper1
- acute kidney injury1
- acute pulmonary oedema1
- african trypanosomiasis relapse1
- agitation1
- asthenia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asphyxia | 2 | 396.3 | 110.7 | 443 |
| acute pulmonary oedema | 1 | 288.3 | 43.9 | 71 |
| seizureSignal | 6 | 84.0 | 46.7 | 415 |
| coma | 2 | 68.0 | 19.0 | 74 |
| treatment failureSignal | 3 | 58.6 | 21.7 | 118 |
| completed suicide | 2 | 38.8 | 10.9 | 41 |
| anaemiaSignal | 3 | 25.4 | 9.4 | 49 |
| agitation | 1 | 22.0 | 3.4 | 5 |
| pyrexiaSignal | 3 | 14.0 | 5.2 | 25 |
| acute kidney injury | 1 | 10.6 | 1.6 | 2 |
| pneumonia | 2 | 10.0 | 2.8 | 9 |
| abdominal pain upper | 1 | 7.9 | 1.2 | 1 |
| headache | 2 | 5.2 | 1.4 | 3 |
| asthenia | 1 | 4.3 | 0.7 | 0 |
| african trypanosomiasis relapse | 1 | 0.0 | 0.0 | 404,887 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.